All In Biotech

Drug Trial Radar · NCT06577441

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

Mar 1, 2027

Study completion Mar 1, 2027

Sponsor

Sponsor type
NIH
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Enasidenib is an enzyme inhibitor that may stop the growth of cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with enasidenib may be effective in treating patients with higher-risk IDH2-mutated MDS.

Conditions

  • Myelodysplastic Syndrome

Interventions

  • Biospecimen CollectionProcedure

    Undergo buccal swab and blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Decitabine and CedazuridineDrug

    Given PO

  • EnasidenibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response (CR) rateTime frame: Up to 4 cycles of treatment

Locations

152 sites in 2 countries. Site status is shown where the registry gives one.

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Active not recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Mills Health Center

    San Mateo, California · Active not recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Memorial Hospital West

    Pembroke Pines, Florida · Recruiting

  • Phoebe Putney Memorial Hospital

    Albany, Georgia · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois · Recruiting

  • Illinois CancerCare-Canton

    Canton, Illinois · Recruiting

  • Illinois CancerCare-Carthage

    Carthage, Illinois · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Swedish Covenant Hospital

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois · Recruiting

  • Decatur Memorial Hospital

    Decatur, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • Illinois CancerCare-Dixon

    Dixon, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Crossroads Cancer Center

    Effingham, Illinois · Recruiting

  • Illinois CancerCare-Eureka

    Eureka, Illinois · Recruiting

  • NorthShore University HealthSystem-Evanston Hospital

    Evanston, Illinois · Recruiting

  • Illinois CancerCare-Galesburg

    Galesburg, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • NorthShore University HealthSystem-Glenbrook Hospital

    Glenview, Illinois · Recruiting

  • Northwestern Medicine Glenview Outpatient Center

    Glenview, Illinois · Recruiting

  • Northwestern Medicine Grayslake Outpatient Center

    Grayslake, Illinois · Recruiting

  • NorthShore University HealthSystem-Highland Park Hospital

    Highland Park, Illinois · Recruiting

  • Edward Hines Jr VA Hospital

    Hines, Illinois · Recruiting

  • Illinois CancerCare-Kewanee Clinic

    Kewanee, Illinois · Recruiting

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois · Recruiting

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.